Expanded Access Part 1: Introduction
What is Expanded Access? FDA Chief Project Manager Monica Hughes discusses a potential pathway for a seriously ill patient to gain access to an investigation…
Related Articles
FDA/The Osteosarcoma Institute (OSI) Workshop
Meeting information for FDA/The Osteosarcoma Institute (OSI) Workshop
FDA approves mitomycin intravesical solution for recurrent low-grade
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
FDA/The Osteosarcoma Institute (OSI) Workshop
Meeting information for FDA/The Osteosarcoma Institute (OSI) Workshop
FDA approves mitomycin intravesical solution for recurrent low-grade
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better – PubMed
Despite survival gains for many pediatric cancers since the 1970s, cancer remains the leading cause of death by disease for children and adolescents in the…
FDA approves darolutamide
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
FDA approves darolutamide
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
FDA approves darolutamide
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.